<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990249</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0209</org_study_id>
    <secondary_id>NCI-2012-01270</secondary_id>
    <nct_id>NCT00990249</nct_id>
  </id_info>
  <brief_title>Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to test the safety of giving clofarabine in
      combination with busulfan, followed by an allogeneic (from a donor) stem cell transplant, in
      patients with advanced leukemia or lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Treatment:

      Busulfan is designed to bind to DNA (the genetic material of cells), which may cause cancer
      cells to die. It is commonly used in stem cell transplants.

      Clofarabine is designed to interfere with the growth and development of cancer cells.

      A stem cell transplant is designed to help your body attack the cancer cells that may remain
      in your body after chemotherapy.

      Central Venous Catheter Placement:

      If you are found to be eligible to take part in this study, you will have a central venous
      catheter (CVC) placed. A CVC is a sterile flexible tube that will be placed into a large vein
      while you are under local anesthesia. Your doctor will explain this procedure to you in more
      detail, and you will be required to sign a separate consent form for it.

      The study drugs and stem cells will be given by vein through your CVC. The CVC will remain in
      your body for about 3 months.

      Study Drug Administration and Stem Cell Transplant:

      You will first receive a low-level &quot;test&quot; dose of busulfan by vein, either over 45 or 60
      minutes, on Day -8 (8 days before the transplant).

      A heparin lock will be placed in your vein to lower the number of needle sticks needed for
      the blood draws. This will involve placing an intravenous (IV) line in your lower arm that
      will remain in place from Day -8 through Day -6.

      Blood (about 1 teaspoon each time) will be drawn for pharmacokinetic (PK) testing up to 11
      times over the 11 hours after the busulfan dose on Day -8. PK testing measures the amount of
      study drug in the body at different time points. This PK testing will be done to find the
      dose of busulfan needed for your body size on the other days that you receive busulfan.

      Each day from Day -6 through Day -3, you will receive clofarabine by vein over 1 hour and
      your body-specific dose of busulfan by vein over 3 hours. If for any reason you could not
      have the PK tests performed, you will receive the standard busulfan dose on these days.

      The PK testing will be repeated on Day -6. Blood (about 1 teaspoon each time) will be drawn
      for PK testing up to 11 times over the 11 hours after the busulfan dose.

      If your donor is not related to you or his/her tissue is not HLA-matched (genetically
      matched), you will receive antithymocyte globulin (ATG) by vein over 4 hours each day on Day
      -3 through Day -1. ATG is designed to weaken your immune system in order to lower the risk
      that your body will reject the transplant.

      On Day 0, you will receive the donor's bone marrow or blood stem cells by vein. The infusion
      will last anywhere from about 30 minutes to several hours.

      You will also receive tacrolimus and methotrexate to weaken the immune system and lower the
      risk of graft-versus-host disease (GVHD). GVHD is a reaction of the donor's immune cells
      against the recipient's body.

        -  Tacrolimus will be given by vein over 24 hours every day, starting on Day -2 and
           continuing until you are able to take tacrolimus by mouth. Once you can take tacrolimus
           by mouth, you will take it every day for about 6 months. If you develop GVHD, the doctor
           may decide you need to take tacrolimus longer than 6 months.

        -  Methotrexate will be given by vein over 15 minutes on Days 1, 3, 6, and 11 after the
           transplant.

      Starting 1 week after the transplant, you will receive filgrastim (G-CSF) as an injection
      under the skin once a day until your blood cell levels return to normal.

      Other Possible Treatments:

      If you have a history of leukemia or lymphoma in the brain, you will receive spinal taps and
      chemotherapy several times over the 12 months after the transplant. The chemotherapy drug
      will be infused over a few minutes, during the spinal tap, directly into the space around the
      spinal cord. Based on standard care, the doctor will decide how often this occurs and which
      chemotherapy drug will be used (either methotrexate or cytarabine).

      If you have a certain type of leukemia (Philadelphia chromosome positive acute lymphoblastic
      leukemia [ALL]), you will receive an additional drug to help prevent the cancer from
      returning. The drug will be imatinib mesylate or another similar type of drug that the doctor
      decides. It will be given by mouth, every day for up to 1 year after the transplant.

      Length of Study Participation:

      You will be in the hospital for about 4 weeks after the transplant. You will be taken off
      study if the disease gets worse. The study drugs will be stopped if intolerable side effects
      occur.

      Follow-Up:

      At 1, 3, 6, and 12 months after the transplant, the following tests and procedures will be
      performed:

        -  Blood (about 4 tablespoons) will be drawn for routine tests.

        -  You will have a bone marrow aspiration to check the status of the disease. To collect a
           bone marrow aspirate, an area of the hip is numbed with anesthetic, and a small amount
           of bone marrow is withdrawn through a large needle.

        -  If the disease was not in your bone marrow at the time of diagnosis, you will have a CT
           and/or positron emission computed tomography (PET) scan to check the status of the
           disease.

      The study staff will stay in contact with your local doctor to find out if the leukemia or
      lymphoma comes back, as well as to check how you are doing.

      This is an investigational study. Busulfan and clofarabine are commercially available and FDA
      approved for the treatment of cancer. Busulfan is also FDA approved for use with stem cell
      transplants. The use of these drugs together with a stem cell transplant is investigational.

      Up to 150 patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Related Mortality (TRM) Defined as Non Relapse Mortality (NRM)</measure>
    <time_frame>100 Days</time_frame>
    <description>NRM was defined as death from any cause other than disease progression or relapse and reported as percentage of participant deaths. Treatment related deaths after transplant are defined either by deaths which could not be attributed to disease relapse or progression or by deaths without previous relapse or progression. For TRM at day 100, Bayesian method of Thall, Simon, and Estey used to perform interim monitoring.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Allogeneic Haematopoietic Stem Cell Transplantation</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Busulfan + Clofarabine + Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan test dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
Clofarabine 40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.
Stem cell infusion on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.</description>
    <arm_group_label>Busulfan + Clofarabine + Stem Cell Transplant</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3</description>
    <arm_group_label>Busulfan + Clofarabine + Stem Cell Transplant</arm_group_label>
    <other_name>Clolar</other_name>
    <other_name>Clofarex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors</description>
    <arm_group_label>Busulfan + Clofarabine + Stem Cell Transplant</arm_group_label>
    <other_name>Anti-thymocyte globulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Busulfan + Clofarabine + Stem Cell Transplant</arm_group_label>
    <other_name>Allogeneic hematopoietic cell transplant</other_name>
    <other_name>HCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with biopsy-proven acute lymphoblastic leukemia, acute lymphoblastic
             lymphoma, or acute biphenotypic leukemia in remission or relapse.

          2. Adequate renal function, as defined by estimated serum creatinine clearance &gt;60
             ml/min.

          3. Bilirubin equal or less than 1.5 (unless Gilbert's Syndrome), serum glutamate pyruvate
             transaminase (SGPT) &lt;3 X upper limit of normal and alkaline phosphatase &lt;2 X upper
             limit of normal.

          4. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced
             vital capacity (FVC) and diffusion capacity of lung for carbon monoxide (DLCO) at
             least 45% of expected corrected for hemoglobin. Children unable to perform pulmonary
             functions must have an oxygen saturation greater than 92% at room air.

          5. Adequate cardiac function with left ventricular ejection fraction at least 45% on
             appropriate medical therapy. No uncontrolled arrhythmias or symptomatic cardiac
             disease.

          6. Zubrod performance status &lt;2 or Lansky/Karnofsky PS equal or greater to 70%.

          7. Patients must have a related, genotypically HLA identical donor, or they must have a
             unrelated donor who is 8/8 HLA match by high resolution typing.

          8. Patient or patient's legal representative, parent(s) or guardian should provide
             written informed consent. Assent of a minor if participant's age is at least seven and
             less than eighteen years.

          9. Negative Beta Human Chorionic Gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months and no previous surgical
             sterilization.

        Exclusion Criteria:

          1. Patients with unresolved grade &gt;2 non-hematologic toxicity from previous therapy.
             Patients with grade 2 toxicity will be eligible at the discretion of the PI.

          2. Patients with active central nervous system (CNS) disease.

          3. Evidence of acute or chronic active hepatitis or cirrhosis.

          4. Uncontrolled infection, including HIV, HTLV-1, hepatitis B or hepatitis C viremia.

          5. Patients greater than 65 years-old.

          6. Prior autologous or allogeneic hematopoietic stem cell transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <results_first_submitted>May 26, 2017</results_first_submitted>
  <results_first_submitted_qc>July 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2018</results_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Acute lymphoblastic lymphoma</keyword>
  <keyword>acute biphenotypic leukemia</keyword>
  <keyword>Allogeneic hematopoietic cell transplantation</keyword>
  <keyword>HCT</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Treatment-related mortality</keyword>
  <keyword>Tyrosine kinase inhibitors</keyword>
  <keyword>TKI</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Myleran</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Clolar</keyword>
  <keyword>Clofarex</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Imatinib Mesylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 01, 2009 to July 13, 2015. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Busulfan + Clofarabine + Stem Cell Transplant</title>
          <description>Busulfan test dose 32 mg/m^2 intravenous (IV) Day -8; following doses Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose. Clofarabine 40 mg/m^2 IV daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg Day -3, 1.5 mg/kg Day -2 &amp; 2.0 mg/kg Day -1 for HLA nonidentical or unrelated donors. Stem cell infusion on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Busulfan + Clofarabine + Stem Cell Transplant</title>
          <description>Busulfan test dose 32 mg/m^2 IV Day -8; following doses Days -6 to -3 derived from PK testing. Clofarabine 40 mg/m^2 IV daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg Day -3, 1.5 mg/kg Day -2 &amp; 2.0 mg/kg Day -1 for HLA nonidentical or unrelated donors. Stem cell infusion on Day 0.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="12" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-Related Mortality (TRM) Defined as Non Relapse Mortality (NRM)</title>
        <description>NRM was defined as death from any cause other than disease progression or relapse and reported as percentage of participant deaths. Treatment related deaths after transplant are defined either by deaths which could not be attributed to disease relapse or progression or by deaths without previous relapse or progression. For TRM at day 100, Bayesian method of Thall, Simon, and Estey used to perform interim monitoring.</description>
        <time_frame>100 Days</time_frame>
        <population>Only 107 participants were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Busulfan + Clofarabine + Stem Cell Transplant</title>
            <description>Busulfan test dose 32 mg/m^2 IV Day -8; following doses Days -6 to -3 derived from PK testing. Clofarabine 40 mg/m^2 IV daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg Day -3, 1.5 mg/kg Day -2 &amp; 2.0 mg/kg Day -1 for HLA nonidentical or unrelated donors. Stem cell infusion on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Mortality (TRM) Defined as Non Relapse Mortality (NRM)</title>
          <description>NRM was defined as death from any cause other than disease progression or relapse and reported as percentage of participant deaths. Treatment related deaths after transplant are defined either by deaths which could not be attributed to disease relapse or progression or by deaths without previous relapse or progression. For TRM at day 100, Bayesian method of Thall, Simon, and Estey used to perform interim monitoring.</description>
          <population>Only 107 participants were evaluated.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The specific period was from the start of preparative regiment up to Day 100 for the collection of adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Busulfan + Clofarabine + Stem Cell Transplant</title>
          <description>Busulfan test dose 32 mg/m^2 IV Day -8; following doses Days -6 to -3 derived from PK testing. Clofarabine 40 mg/m^2 IV daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg Day -3, 1.5 mg/kg Day -2 &amp; 2.0 mg/kg Day -1 for HLA nonidentical or unrelated donors. Stem cell infusion on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diffuse alveolar hemorrhage (DAH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="47" subjects_affected="43" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="65" subjects_affected="63" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="56" subjects_affected="56" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="105" subjects_affected="105" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="248" subjects_affected="92" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE v4.0">Bilirubin</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Shortness of Breath (SOB)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diffuse Alveolar Hemorrahge (DAH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive disease (VOD)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypertension (HTN)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Partow Kebriaei, MD/Professor, Stem Cell Transplantation</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

